Wpływ edukacji chorego na skuteczność terapii wziewnej w POChP i astmie Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
sty 5, 2023
Słowa kluczowe:
astma, terapia, compliance, edukacja, inhalator
##plugins.themes.bootstrap3.article.main##
Abstrakt
Astma i przewlekła obturacyjna choroba płuc są chorobami przewlekłymi, a skuteczność ich terapii zależy nie tylko od wyboru odpowiedniej metody leczenia, ale także od świadomości pacjenta. Z tego względu lekarze przy każdym kontakcie z chorym powinni rozważyć jego edukowanie. Właściwa edukacja zapewnia wyższy stopień przestrzegania zaleceń lekarskich i compliance, co w istotny sposób wpływa na szanse powodzenia terapii. Edukacja w zakresie samej choroby, jej leczenia powinna być obecna przy ustalaniu rozpoznania choroby, na wizytach kontrolnych, a także w sytuacji braku kontroli objawów chorobowych – przed eskalacją terapii. Ważnym aspektem edukacji pacjenta jest także nauka poprawnej techniki aplikacji leków w odpowiednio dobranych podajnikach czy systemach inhalacyjnych.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Poziomkowska-Gęsicka, I., & Gazdowska, M. (2023). Wpływ edukacji chorego na skuteczność terapii wziewnej w POChP i astmie . Alergoprofil, 18(4), 21-25. https://doi.org/10.24292/01.AP.184059123
Numer
Dział
THERAPY
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021 (access: 27.02.2023).
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022 (access: 27.02.2023).
3. Gaciong Z, Kardas P. Nieprzestrzeganie zaleceń terapeutycznych. Naukowa Fundacja Polpharmy, Warszawa 2015.
4. Dońka K, Czerwińska-Pawluk I, Paździor V et al. Przyczyny braku kontroli astmy na podstawie literatury. J Educ Health Sport. 2015; 5(1): 263-73.
5. Herndon JB, Mattke S, Evans Cuellar A et al. Anti-inflammatory medication adherence, healthcare utilization and expenditures among Medicaid and children’s health insurance program enrollees with asthma. Pharmacoeconomics. 2012; 30(5): 397-412.
6. Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol. 2006; 118(4): 899-904.
7. Makhinova T, Barner JC, Richards KM et al. Asthma Controller Medication Adherence, Risk of Exacerbation, and Use of Rescue Agents Among Texas Medicaid Patients with Persistent Asthma. J Manag Care Spec Pharm. 2015; 21(12): 1124-32.
8. Ismaila A, Corriveau D, Vaillancourt J et al. Impact of adherence to treatment with fluticasone propionate/salmeterol in asthma patients. Curr Med Res Opin. 2014; 30(7): 1417-25.
9. Price D, Bosnic-Anticevich S, Briggs A et al. Inhaler Error Steering Committee: Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013; 107: 37-46.
10. Górska K, Korczyński P. The role of education of patients with asthma and chronic obstructive pulmonary disease in outpatient settings. Lekarz POZ. 2019; 5(6): 411-8.
11. Sauriasari R, Madani RA, Rozaliyani A et al. The effect of repeated education using live demonstrations and videos of how to use inhalation drugs on quality of life for COPD patients. Heliyon. 2021; 7(9): e07870. http://doi.org/10.1016/j.heliyon. 2021.e07870.
12. Melzer AC, Ghassemieh BJ, Gillespie SE et al. Patient characteristics associated with poor inhaler technique among a cohort of patients with COPD. Respir Med. 2017; 123: 124-30. http://doi.org/10.1016/j.rmed.2016.12.011.
13. Takaku Y, Kurashima K, Ohta C et al. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? Respir Med. 2017; 123: 110-5. http://doi.org/10.1016/j.rmed.2016.12.012.
14. Gallefoss F, Bakke PS. Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease. Respir Med. 2000; 94(3): 279-87. http://doi.org/10.1053/rmed.1999.0749.
15. Gallefoss F. The effects of patient education in COPD in a 1-year follow-up randomised, controlled trial. Patient Educ Couns. 2004; 52(3): 259-66. http://doi.org/10.1016/S0738-3991(03)00100-9.
16.Sari N, Osman M. The effects of patient education programs on medication use among asthma and COPD patients: a propensity score matching with a difference-in-difference regression approach. BMC Health Serv Res. 2015; 15: 332. http://doi.org/10.1186/s12913-015-0998-6.
17. Malerba M, Foci V, Patrucco F et al. Single Inhaler LABA/ LAMA for COPD. Front Pharmacol. 2019; 10: 390. http://doi.org/10.3389/fphar.2019.00390.
18. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. Via Medica, Gdańsk 2015: 1-22.
19. Emeryk A, Pirożyński M, Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018; 86: 44-52.
20. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005; 50: 1209-27.
21. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy-volunteers – implications for in-vitro testing. J Aerosol Med. 1993; 6: 99-110.
22. Demoly P, Hagedoorn P, De Boer AH et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med. 2014; 108(8): 1195-203.
23. Molimard M, Raherison C, Lignot S et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017; 49(2): 1601794.
24. Asaris, proszek do inhalacji – charakterystyka produktu leczniczego.
25. Braido F, Brusselle G, Guastalla D et al. Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study. Respir Res. 2016; 17(1): 51.
26. Kang H-R, Song HJ, Nam JH et al. Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea. BMJ Open. 2018; 8(3): e020825.
27. Lindsay JT, Heaney LG. Nonadherence in difficult asthma – facts, myths, and a time to act. Patient Prefer Adherence. 2013; 7: 329-36.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022 (access: 27.02.2023).
3. Gaciong Z, Kardas P. Nieprzestrzeganie zaleceń terapeutycznych. Naukowa Fundacja Polpharmy, Warszawa 2015.
4. Dońka K, Czerwińska-Pawluk I, Paździor V et al. Przyczyny braku kontroli astmy na podstawie literatury. J Educ Health Sport. 2015; 5(1): 263-73.
5. Herndon JB, Mattke S, Evans Cuellar A et al. Anti-inflammatory medication adherence, healthcare utilization and expenditures among Medicaid and children’s health insurance program enrollees with asthma. Pharmacoeconomics. 2012; 30(5): 397-412.
6. Bender BG, Pedan A, Varasteh LT. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. J Allergy Clin Immunol. 2006; 118(4): 899-904.
7. Makhinova T, Barner JC, Richards KM et al. Asthma Controller Medication Adherence, Risk of Exacerbation, and Use of Rescue Agents Among Texas Medicaid Patients with Persistent Asthma. J Manag Care Spec Pharm. 2015; 21(12): 1124-32.
8. Ismaila A, Corriveau D, Vaillancourt J et al. Impact of adherence to treatment with fluticasone propionate/salmeterol in asthma patients. Curr Med Res Opin. 2014; 30(7): 1417-25.
9. Price D, Bosnic-Anticevich S, Briggs A et al. Inhaler Error Steering Committee: Inhaler competence in asthma: common errors, barriers to use and recommended solutions. Respir Med. 2013; 107: 37-46.
10. Górska K, Korczyński P. The role of education of patients with asthma and chronic obstructive pulmonary disease in outpatient settings. Lekarz POZ. 2019; 5(6): 411-8.
11. Sauriasari R, Madani RA, Rozaliyani A et al. The effect of repeated education using live demonstrations and videos of how to use inhalation drugs on quality of life for COPD patients. Heliyon. 2021; 7(9): e07870. http://doi.org/10.1016/j.heliyon. 2021.e07870.
12. Melzer AC, Ghassemieh BJ, Gillespie SE et al. Patient characteristics associated with poor inhaler technique among a cohort of patients with COPD. Respir Med. 2017; 123: 124-30. http://doi.org/10.1016/j.rmed.2016.12.011.
13. Takaku Y, Kurashima K, Ohta C et al. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? Respir Med. 2017; 123: 110-5. http://doi.org/10.1016/j.rmed.2016.12.012.
14. Gallefoss F, Bakke PS. Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease. Respir Med. 2000; 94(3): 279-87. http://doi.org/10.1053/rmed.1999.0749.
15. Gallefoss F. The effects of patient education in COPD in a 1-year follow-up randomised, controlled trial. Patient Educ Couns. 2004; 52(3): 259-66. http://doi.org/10.1016/S0738-3991(03)00100-9.
16.Sari N, Osman M. The effects of patient education programs on medication use among asthma and COPD patients: a propensity score matching with a difference-in-difference regression approach. BMC Health Serv Res. 2015; 15: 332. http://doi.org/10.1186/s12913-015-0998-6.
17. Malerba M, Foci V, Patrucco F et al. Single Inhaler LABA/ LAMA for COPD. Front Pharmacol. 2019; 10: 390. http://doi.org/10.3389/fphar.2019.00390.
18. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. Via Medica, Gdańsk 2015: 1-22.
19. Emeryk A, Pirożyński M, Emeryk-Maksymiuk J. Dry powder inhalers – between the doctor and the patient. Adv Respir Med. 2018; 86: 44-52.
20. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Respir Care. 2005; 50: 1209-27.
21. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy-volunteers – implications for in-vitro testing. J Aerosol Med. 1993; 6: 99-110.
22. Demoly P, Hagedoorn P, De Boer AH et al. The clinical relevance of dry powder inhaler performance for drug delivery. Respir Med. 2014; 108(8): 1195-203.
23. Molimard M, Raherison C, Lignot S et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017; 49(2): 1601794.
24. Asaris, proszek do inhalacji – charakterystyka produktu leczniczego.
25. Braido F, Brusselle G, Guastalla D et al. Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study. Respir Res. 2016; 17(1): 51.
26. Kang H-R, Song HJ, Nam JH et al. Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea. BMJ Open. 2018; 8(3): e020825.
27. Lindsay JT, Heaney LG. Nonadherence in difficult asthma – facts, myths, and a time to act. Patient Prefer Adherence. 2013; 7: 329-36.